Agenus Inc. (AGEN)
$
2.85
-0.13 (-4.56%)
Key metrics
Financial statements
Free cash flow per share
-2.8009
Market cap
96.9 Million
Price to sales ratio
0.9073
Debt to equity
-0.1670
Current ratio
0.4665
Income quality
2.3279
Average inventory
0
ROE
0.1085
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agenus Inc., a clinical-stage immuno-oncology company operating in the United States and internationally, is focused on discovering and developing innovative immuno-oncology products. The company's operating income ratio is -1.16 indicating the company's operational profitability margin. Additionally, the gross profit ratio is -0.51 reflecting the efficiency of the company's production and sales operations. Agenus Inc. leverages its Retrocyte Display, an advanced antibody expression platform, for identifying fully human and humanized monoclonal antibodies. The organization also develops various vaccine programs, including the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Its product pipeline features several promising candidates, such as Balstilimab, an anti-PD-1 antagonist that has completed a Phase II clinical trial for second line cervical cancer, AGEN1181, an anti-CTLA-4 monospecific antibody currently in Phase 1/2 clinical trial, and AGEN2373, an anti-CD137 monospecific antibody in Phase 1 clinical trial. Other notable developments include AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has finished its Phase 1 clinical trial, and AGEN1777, an anti-TIGIT bispecific antibody. Furthermore, AGEN1327 is a human monoclonal antibody, while INCAGN1876, INCAGN1949, INCAGN2390, and INCAGN2385 are specialized anti-GITR, anti-OX40, anti-TIM-3, and anti-LAG-3 monoclonal antibodies, respectively. The company also has ARDS-targeting AGENT 797 in Phase 1 clinical trials, and AGEN1884, a first-generation anti-CTLA-4 antibody. Agenus collaborates with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. was formerly known as Antigenics Inc. and rebranded in January 2011. The company reported depreciation and amortization expenses of $13,343,000.00 reflecting the wear and tear of its assets. The EBITDA is -$101,302,000.00 a key indicator of the company's operational profitability. The financial data pertains to the fiscal year 2024. As a small-cap player with a market capitalization of $96,923,655.00 Agenus controls a pivotal role in the Biotechnology industry, making significant contributions to the overall market landscape. The stock is affordable at $4.38 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 670,053.00 indicating lower market activity. The company belongs to the Healthcare sector, driving innovation and growth within the evolving landscape of immuno-oncology.
Is Agenus Inc. (AGEN) a good investment?
Investing in Agenus Inc. (AGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Agenus Inc. (AGEN)'s stock forecast?
Analysts predict Agenus Inc. stock to fluctuate between $1.38 (low) and $7.34 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agenus Inc.'s market capitalization?
As of 2026-02-12, Agenus Inc.'s market cap is $96,923,655, based on 34,008,300 outstanding shares.
How does Agenus Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agenus Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agenus Inc. (AGEN) stock?
To buy Agenus Inc. (AGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGEN. Place an order (Market, Limit, etc.).
What is the best time to invest in Agenus Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Agenus Inc. stock ever split?
Agenus Inc.'s last stock split was 1:20 on 2024-04-12.
How did Agenus Inc. perform in the last earnings report?
Revenue: $103,463,000 | EPS: -$10.59 | Growth: -22.98%.
Where can I find Agenus Inc.'s investor relations reports?
Visit https://www.agenusbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agenus Inc.?
You can explore historical data from here
What is the all-time high and low for Agenus Inc. stock?
All-time high: $135.80 (2021-08-30) | All-time low: $1.38 (2025-04-07).
What are the key trends affecting Agenus Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL). The expansion reflects increasing interest from treating oncologists worldwide seeking access to BOT+BAL for p.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Access--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus' Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET. The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus' botensilimab and balstilimab (BOT+BAL) program entering 2026. The ses.
prnewswire.com
AHMEDABAD, India and PENNINGTON, N.J., Jan. 15, 2026 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") is an innovation-led life-sciences company with an international presence, today announced the successful closure of the Asset Purchase Agreement, Share Purchase Agreement, and the exclusive Licensing Agreement with Agenus Inc. (NASDAQ: AGEN).
zacks.com
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer,” i.
seekingalpha.com
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (.
zacks.com
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Fr.
See all news
